NextCure (FRA:2US) Total Liabilities : €14.82 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Total Liabilities?

NextCure's Total Liabilities for the quarter that ended in Mar. 2024 was €14.82 Mil.

NextCure's quarterly Total Liabilities declined from Sep. 2023 (€12.64 Mil) to Dec. 2023 (€12.49 Mil) but then increased from Dec. 2023 (€12.49 Mil) to Mar. 2024 (€14.82 Mil).

NextCure's annual Total Liabilities increased from Dec. 2021 (€7.97 Mil) to Dec. 2022 (€15.70 Mil) but then declined from Dec. 2022 (€15.70 Mil) to Dec. 2023 (€12.49 Mil).

NextCure Total Liabilities Historical Data

The historical data trend for NextCure's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Total Liabilities Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

31.22

10.62

7.97

15.70

12.49

NextCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															12.69	13.80	12.64	12.49	14.82

NextCure Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NextCure's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.312	+	(5.455	+	0.72
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.49

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	117.411	-	104.924
	=	12.49

NextCure's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.816	+	(5.311	+	0.695
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	14.82

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	105.946	-	91.124
	=	14.82

NextCure Total Liabilities Related Terms

Thank you for viewing the detailed overview of NextCure's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (FRA:2US) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines